Opthea Ltd. (OPT) reported the grant of Japanese patent covering both OPT-302 and compositions containing OPT-302 for use in treating disorders associated with aberrant angiogenesis and/or lymphangiogenesis, including eye diseases such are wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Patents covering Opthea's OPT-302 and extending out to 2034 have now been granted in Japan, the U.S.A., Australia, South Africa and Singapore and applications are pending in a further 14 countries
http://crweworld.com/article/news-provided-by-globenewswire/957450/opthea-granted-japanese-patent-covering-opt-302
Opthea Ltd. (OPT) reported the grant of Japanese patent covering...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 121324 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 90033 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |